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ABSTRACT
Aim: Hyperthermia (HT) has been shown to improve clinical response to radiation therapy (RT) for can-
cer. Synergism is dramatically enhanced if HT and RT are combined simultaneously, but appropriate
technology to apply treatments together does not exist. This study investigates the feasibility of deliv-
ering HT with RT to a 5-10mm annular rim of at-risk tissue around a tumor resection cavity using a
temporary thermobrachytherapy (TBT) balloon implant.
Methods: A balloon catheter was designed to deliver radiation from High Dose Rate (HDR) brachyther-
apy concurrent with HT delivered by filling the balloon with magnetic nanoparticles (MNP) and
immersing it in a radiofrequency magnetic field. Temperature distributions in brain around the TBT
balloon were simulated with temperature dependent brain blood perfusion using numerical modeling.
A magnetic induction system was constructed and used to produce rapid heating (>0.2C/s) of MNP-
filled balloons in brain tissue-equivalent phantoms by absorbing 0.5 W/ml from a 5.7 kA/m field at
133 kHz.
Results: Simulated treatment plans demonstrate the ability to heat at-risk tissue around a brain tumor
resection cavity between 40-48C for 2-5cm diameter balloons. Experimental thermal dosimetry verifies
the expected rapid and spherically symmetric heating of brain phantom around the MNP-filled balloon
at a magnetic field strength that has proven safe in previous clinical studies.
Conclusions: These preclinical results demonstrate the feasibility of using a TBT balloon to deliver
heat simultaneously with HDR brachytherapy to tumor bed around a brain tumor resection cavity,
with significantly improved uniformity of heating over previous multi-catheter interstitial approaches.
Considered along with results of previous clinical thermobrachytherapy trials, this new capability is
expected to improve both survival and quality of life in patients with glioblastoma multiforme.
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1. Introduction
Surgery is a critical component of therapy for many cancer
patients, but effective therapy often requires post-surgical
treatment of micrometastatic deposits of tumor cells that
infiltrate normal tissues around the resection cavity.
Radiation therapy (RT) of the tumor bed improves clinical
response, but RT dose is limited by normal tissue toxicity.
For aggressive tumors like glioblastoma multiforme (GBM),
external beam radiation (EBRT) is normally delivered in 5 day/
week fractions over 6weeks [1]. Despite treatment that gen-
erally includes temozolomide (TMZ) chemotherapy, patients
typically fail locally with median survival approximately
18months for primary GBM and 12months for recurrent
GBM [2–7]. Alternatively, there are approaches that localize
higher doses of RT to at-risk tissues around the resection
cavity by: (a) temporarily implanting an array of catheters to
insert radioactive seeds that deliver RT over 3–5 days; (b) per-
manently implanting an array of short half-life RT seeds that
deliver dose slowly over 4–5weeks; or (c) placing an inflat-
able balloon in the resection cavity at the time of surgery
with a catheter exiting the skin for subsequent insertion of
either a radioactive fluid or High Dose Rate (HDR) source to
deliver radiation over 1–5 days before withdrawing the bal-
loon. FDA-approved inflatable balloon medical devices have
been developed to deliver brachytherapy in brain [8], breast
[9,10], and other sites. The current effort investigates a
brachytherapy balloon implant that adds the capability of
simultaneous thermal therapy to boost clinical outcomes in
aggressive brain cancers.
Combining thermal therapy (40–48 C for 15–60min) with
radiation has been proven to enhance radiation response
both in vitro and in vivo [11–13] as well as improve clinical
outcomes in 24 positive randomized clinical trials [14,15].
Particularly relevant for brain tumor therapy is one random-
ized trial in primary GBM that demonstrated a statistically
significant doubling of 2-year survival (31 vs. 15%, p¼ .02) by
adding two 30min treatments with interstitial microwave
hyperthermia to the then standard of care: regional brain
RTþ oral hydroxyureaþ interstitial seed brachytherapy boost
to tumor bed [16]. A similar trial investigated adding thermo-
therapy via implanted ferromagnetic seeds to an
EBRTþbrachytherapy regimen and demonstrated a 47% 2-
year survival in primary high-grade gliomas [17]. The 31% and
47% 2-year survival rates obtained in these 1990s brain tumor
trials remain among the best clinical outcomes for GBM to
date, and clearly demonstrate the benefit of adjuvant hyper-
thermia even when not optimally delivered. Unfortunately, the
university-developed heating technologies used in those two
trials were never made available commercially and these
promising thermoradiotherapy approaches could not be incor-
porated into clinical practice. Subsequently, a new approach
for heating brain tumors was developed based on inductively
heating magnetic nanoparticles that are injected via multiple
needle tracks into the tumor volume. Using a commercially
available magnetic induction system, clinical trials have dem-
onstrated a median survival of 23.2mo for primary GBM using
nanoparticle heating in combination with fractionated stereo-
tactic RT [18,19]. As additional rationale to accelerate use of
adjuvant heat in treating GBM, we point to critically important
preclinical in vivo murine studies that demonstrate a dramatic
escalation of thermal enhancement ratio (TER) from 1.5 for
sequential heat and radiation, as used in previous clinical
studies, to 5.0 for simultaneous treatments [12,13]. The impact
of increased synergism between HT and RT when delivered
concomitantly and at higher thermal dose levels is that clinical
response with adjuvant HT can be increased up to 5 times
higher than with RT alone. Unfortunately, there is no commer-
cially available technology to apply HT and RT simultaneously
in human brain.
To address this need, our proposed approach is a straight-
forward combination of previous technology that should pro-
vide improved uniformity of both HT and RT dose around a
tumor resection cavity as well as enable simultaneous deliv-
ery for maximum TER. To implement this treatment strategy,
we will construct a dual-modality thermobrachytherapy (TBT)
device from an inflatable balloon with catheters extending
from the resection cavity outside the skull for insertion of
HDR brachytherapy source, saline, magnetic nanoparticle
(MNP) solution, and temperature sensor (see Figure 1). After
surgical placement of the balloon catheter at time of tumor
debulking, the inner balloon will be filled with saline to
expand the resection cavity into approximately spherical
shape. After magnetic resonance (MR) imaging for treatment
planning, some of the saline will be replaced with an equiva-
lent volume of MNP solution in the outer balloon and the
central catheter connected to a commonly available HDR
remote afterloader. The patient will sit or lie with their head
inside a non-contacting induction coil that generates a mag-
netic field within the brain for 30min while HDR brachy-
therapy is administered from a source inserted to the
balloon center. Simultaneous heat and brachytherapy will be
administered in a single dose immediately after surgery, or
the combination treatment repeated daily for up to a week
before removal of the balloon under local anesthetic. The
clinical consequence is a single surgery implant that provides
higher and more uniform radiation dose to a spherically sym-
metric tumor bed than alternative approaches, with simul-
taneous thermotherapy to enhance RT response locally while
minimizing toxicity. The HDR source, MNP, and deflated bal-
loon are easily withdrawn at the end of therapy to complete
the intervention in 1week. This procedure will reduce over-
all treatment time and cost, eliminate irradiation of surround-
ing normal tissue, and reduce neurocognitive deficit that
often accompanies regional treatment of brain.
Optimum treatment of GBM remains a controversial sub-
ject. Clinical trials have investigated numerous combinations
of external beam radiation, systemic chemotherapy [2,20],
focused stereotactic radiosurgery [21], local radiation boost
to tumor bed via interstitial implant [22,23], GammaTile ther-
apy [24], local chemotherapy (e.g., carmustine or GliadelVR
wafers) [16,17,19,25,26] and/or immunotherapy [27,28].
Additionally, several trials have investigated local hyperther-
mia as a means to enhance radiation response while mini-
mizing peripheral normal tissue toxicity [16,17,19]. Overall,
median survival remains stubbornly under 24months for pri-
mary GBM regardless of approach. Although some of the
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best 2-year survival results were reported in the 1990s by
Sneed et al. [16] and Stea et al. [17] where they combined
EBRT with systemic chemotherapy and local brachytherapy
plus interstitial HT, neither investigator used FDA-approved
heating technology and the promising investigations ended
with the end of grant funding. After over 20 years, overall
median survival for primary GBM remains lower than was
obtained in those three hyperthermia trials even with advan-
ces such as improved radiation delivery, TMZ, and other tar-
geted agents and immune boosts.
The primary goal of this effort is to demonstrate feasibility
of a novel combination thermobrachytherapy balloon device
that should facilitate new clinical trials to investigate simul-
taneous heat and radiation delivered uniformly and well-
localized in tumor bed immediately after surgery, before
tumor cell migration into surrounding normal brain. This ini-
tial study focuses on thermal performance of a TBT balloon
since the dosimetry of HDR radiation from within an
implanted balloon catheter source is already well-character-
ized in the literature for soft tissue sites including brain and
breast [9,29,30]. Subsequent in vivo studies and clinical trials
with the proposed thermobrachytherapy device will be
required to determine: (a) optimum balloon temperature and
penetration depth of therapy for brain; (b) optimum brachy-
therapy dose for combined therapy; (c) optimum fraction-
ation of heat and brachytherapy; and (d) whether
combination strategies of thermobrachytherapy with EBRT,
chemotherapy, temozolomide, and/or immunotherapy would
be beneficial for GBM and other resected brain tumors.
2. Materials and methods
2.1. Thermobrachytherapy balloon implant
The thermobrachytherapy (TBT) balloon design is illustrated
in Figure 1. It will be fabricated from an FDA-approved
extruded plastic shaft and molded balloons (in several diam-
eters), and integrated with commercially available catheter
materials. The dual-balloon design is proposed to enable
inflation of the inner balloon with inexpensive saline to
expand the resection cavity into approximately spherical
shape and filling of the outer balloon with a MNP solution
that absorbs energy from an external magnetic field to gen-
erate heat. The MNP solution and magnetic field are homo-
genous, thus produce equal temperature of the balloon
surface in contact with the wall of the resection cavity. In
order to heat the entire tumor bed to a therapeutic tempera-
ture range of 40–48 C, a radiofrequency current will be
driven through a non-contacting induction coil that encircles
the head to couple energy into the MNP solution. Power will
be adjusted to maintain balloon surface temperature at the
prescribed therapeutic level, which is calculated during HT
treatment planning and monitored during treatment with a
fiberoptic temperature sensor in the outer balloon. During
heating, a single HDR radiation source will be driven by a
standard clinical remote afterloader to the center of the
inner balloon to deliver radiation uniformly to the nearly
spherical resection cavity wall. This simultaneous heat and
radiation treatment will be repeated daily for up to one
week post-surgery. After this treatment, the balloon will be
deflated and the device retracted through the skin in a
minor procedure with local anesthetic at the scalp exit point.
2.2. Magnetic nanoparticles
Magnetic nanoparticles have been widely investigated for
clinical applications ranging from contrast enhancement of
MR imaging [31,32] to hyperthermia therapy for cancer
[33,34]. Iron oxide magnetic nanoparticles may be purchased
from commercial suppliers such as Sigma-Aldrich Corp. (St.
Louis, MO), Micromod Partikeltechnologie GmbH (Rostok,
Figure 1. Thermobrachytherapy balloon design. The outer balloon is filled with MNP to heat tumor bed and the inner balloon is inflated with saline to expand the
resection cavity wall into more advantageous near-spherical geometry. A catheter extends through the flexible shaft and along the outer balloon wall to insert a
temperature monitoring and control sensor. A central catheter extends from the surface to the balloon center for inserting an HDR radiation source. Two catheters
extend from valved ports to fill the balloons with saline and MNP solution.
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Germany), Nanocs Inc. (New York, NY), or others. Following
preliminary power absorption studies with various formula-
tions and iron concentrations, the nanoparticles chosen as
optimum for the current investigation were obtained from
Micromod Partikeltechnologie GmbH (Rostok, Germany) as
Perimag-CR with 130 nm size and iron concentration of
17.1mg/mL. The nanoparticles were prepared and bottled in
a cleanroom according to EU GMP guidelines.
2.3. Magnetic field generating system
The experimental system used to activate the nanoparticle
filled balloons consists of a 7.5 kW, 80–180 kHz induction
heating system assembled with an elliptically shaped
26 31 20 cm3 coil which is appropriately sized to accom-
modate the human head (AMF Life Systems, Auburn Hills
MI). The system shown in Figure 2 was configured to pro-
duce a magnetic field strength in the range 1.98.1 kA/m at
133 kHz in the central volume of the coil. The coil length and
elliptical dimensions, including protective housing, were opti-
mized to produce a more uniform field well-matched to the
human head for maximum differential power absorption in a
nanoparticle-filled balloon relative to direct heating of brain
tissue [35]. Field uniformity within the coil was assessed with
a 1 cm diameter magnetic field probe (AMF Life Systems,
Auburn Hills MI) mapped in 1 cm increments along 43 axial
tracks measuring field strength throughout the coil from end
to end and from coil center to outer plastic casing.
2.4. Laboratory measurement of balloon
implant heating
Rate of temperature rise tests were used to characterize
power absorption in the nanoparticle fluid as a function of
field strength. A fixed volume of nanoparticle fluid was
placed in a test chamber in the center of the coil with mag-
netic field probe and temperature sensors immediately
adjacent to the fluid. To establish reproducibility of heating
and stability of the MNP solution during heating, multiple
independent experiments were performed at field strengths
ranging from 4.68.1 kA/m over a period of 5months, while
storing the test solution in a refrigerator between heat
experiments. Due to the lack of preferred fiberoptic therm-
ometry, temperature monitoring for the heating rate studies
was provided by a 16-channel Hioki Data Acquisition Device
(Hioki USA, Cranbury NJ) with 40 gauge Type E thermocou-
ples. Wires were oriented perpendicular to the magnetic field
as possible to minimize interference on the readout. A field-
dependent <2 C artifact was evident on the readout which
remained constant throughout the heating period and thus
did not affect heating rate calculations.
For more realistic modeling of balloon heating in a non-
perfused thermal load, a split-apart, 3-D printed full size
human head phantom was constructed and filled with TX-
151 gel phantom with thermal conductivity similar to human
brain white matter. A 2-cm diameter MNP-filled test balloon
(GliaSiteVR ) was inserted 3–5 cm deep in the brain/skull phan-
tom and placed in the center of the induction coil (Figure 3).
Temperatures were monitored with Type E thermocouples
located 0, 2.5, 5, 7.5, 10 and 12.5mm from the balloon sur-
face during application of the magnetic field to characterize
radial penetration of heating around the balloon. In a separ-
ate heating procedure with no internal thermocouple probes,
the brain phantom was removed from the induction coil and
the two halves were separated immediately after heating.
The two-dimensional temperature distribution induced in the
central cross-section of the brain gel phantom
through the center of balloon was recorded with a thermal
imaging camera (Model PT1-170L-HT, Process Sensors
Corporation, Germany).
2.5. Simulation of balloon implant heating
Computer modeling of TBT balloon implant heating was per-
formed in a human brain model to determine expected tem-
perature distributions around the implant as a function of
balloon diameter (d¼ 2, 3, 4 or 5 cm) and power (P)
absorbed in the MNP solution from the magnetic field.
Power was optimized to produce a minimum temperature of
40 C throughout a 5-mm annular shell of tumor bed tissue.
Temperature simulations were computed using the bioheat
equation [36] (Equation 1) in a three-layer spherical model
consisting of: a sphere representing the MNP solution with
diameter d, a 5-mm annular shell surrounding the MNP
domain corresponding to the tissue target, and a concentric
sphere with a radius rext ¼ dþ 5.5 cm corresponding to the




¼ r  krTð Þ þ xbcb Tb  Tð ÞFðTÞ þ Qmet (1)
where t is time, T is temperature, Tb is arterial blood tem-
perature (37 C), b index corresponds to blood, and the
remaining properties are introduced in Table 1. To provide
more realistic temperature estimations in the human brain,
we accounted for the temperature-dependence of blood
Figure 2. Photograph of laboratory induction heating system used for initial
characterization of heating from MNP-filled balloon implants, including radio-
frequency power amplifier, matching network and water-cooled
26 31 20 cm3 head coil (AMF Life Systems, Auburn Hills MI).
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perfusion by introducing a scaling function F(T) given by:
FðTÞ ¼




, T  Tcr








with a, b and c being curve-fitting parameters retrieved from
experiments and Tcr the critical temperature at which perfu-
sion starts to decrease due to thermal damage to the vascu-
lature. Below Tcr, the scaling function presents a Gaussian
profile that was first introduced by Tompkins et al. [38] and
refined by Lang et al. [39] for muscle, fat, and tumor tissues.
Based on the experimental measurements in large mammals
by Lyons et al. [40] and Satoh et al. [41], we assume that the
maximum blood perfusion occurs at 45 C (¼Tcr) with a 2.5-
fold increase above baseline xb, which results in a¼ 1.5. The
parameter b is assumed to be the same as muscle: b¼ 12
[39]. The perfusion behavior above Tcr has not been charac-
terized for brain tissue. Thus, we developed a scaling func-
tion F(T) for T > Tcr assuming the same Gaussian profile, but
with the equation recalibrated to enforce zero blood perfu-
sion above 48 C [42], yielding c¼ 3.1588.
For this proof of concept simulation, we used homoge-
neous white matter properties for the 5-mm target and sur-
rounding tissue (Table 1). The MNP-mimicking heat source is
embodied in an inward heat flux boundary condition given
by q0 ¼ pd2P/16 (units of W/m2), imposed at the implant sur-
face at radius r¼ d/2. A convective heat flux was imposed at
the external domain boundary (rext) with a convective coeffi-
cient of 200W/m2/K and a temperature of 37 C to account
for surrounding convective losses due to blood flow and tis-
sue perfusion [43]. The simulations were performed in
COMSOL Multiphysics v5.4 (Comsol Inc., Burlington MA).
Finally to generate a mesh-independent solution, the mesh
was refined so the maximum and minimum temperatures in
the target did not change more than 0.002 C between mesh
refinements. The resulting mesh parameters are shown in
Table 2.
3. Results
Magnetic field measurements inside the head coil are shown
in Figure 4 for 1.9 kW of applied power at 133 kHz. Note the
large >10 cm diameter sweet spot near the coil center where
the 5.2 kA/m field varies less than ± 10%. This level of field
uniformity should produce nearly homogeneous power
deposition in the 2–5 cm diameter MNP filled balloons
regardless of location within the skull.
Figure 5(A) shows the reproducibility of power coupling
into a MNP-filled test chamber with nine independent experi-
ments using three different magnetic field strengths at
133 kHz. Note the nearly identical MNP heating rates
obtained at each field strength during repeated trials. The
two trials at 4.6 kA/m, five trials at 4.9 kA/m, and two trials at
5.3 kA/m are nearly indistinguishable on the plot, demon-
strating the expected reproducibility of power absorption in
magnetic nanoparticle fluid over both time and repeated
field exposures.
As a more realistic test of heating capability, a GliaSiteVR
balloon filled with 4.2mL of MNP with 17mg/mL Fe was
inserted 4-cm deep in a life-size split-apart skull/brain tissue
model having thermal properties similar to zero perfusion
Figure 3. Experimental setup of magnetic nanoparticle (MNP) balloon implant heating: (A) 2-cm diameter MNP-filled balloon buried 4-cm deep in the central plane
of a split-apart human skull model that is filled with brain tissue-equivalent phantom and 2.5-mm spaced thermocouples to measure radial penetration of heating.
(B) Split-apart skull/brain model assembled inside the head coil for application of radiofrequency magnetic field.
Table 1. Thermal and physiological properties used in the numerical simula-
tions [37].
Property Tissue White matter Blood
Density, q (kg/m3) 1041 1050
Specific heat capacity, c (J/kg/K) 3583 3617
Thermal conductivity, k (W/m/K) 0.48 –
Blood perfusion rate, xb (kg/s/m
3) 3.87 –
Metabolic heat generation rate, Qmet (W/m
3) 4498 –
INTERNATIONAL JOURNAL OF HYPERTHERMIA 1193
white matter. After assembling the two halves of brain phan-
tom in the center of the head coil and applying a 5 kA/m
magnetic field at 133 kHz, temperature rise was highest at
the balloon surface and fell off with increasing distance from
the balloon as seen in Figure 6. After 30min of heating, the
temperature rise was 23 C at the balloon surface, 14 C at
5mm, and 9 C at 10mm radial distance from the balloon.
The uniformity of heating all around a MNP-filled balloon
implant was assessed with a thermographic camera to cap-
ture the complete two dimensional heating pattern in the
mid-depth cross-section of the split apart skull/brain phan-
tom model. Figure 7(A) shows the geometry of the 2-cm
diameter balloon centered in the life size head phantom.
Figure 7(B) shows the thermal image obtained within 20 s
after immersing the skull phantom in a 133 kHz magnetic
field of 6.9 kA/m for 15min followed by 6.2 kA/m for 5min.
As seen in Figure 7(C), the balloon surface temperature rose
31 C above initial phantom temperature and fell off sym-
metrically in all directions. Temperatures throughout the 5-
mm annular shell of ‘target tissue’ rose at least 15 C or half
the temperature rise of the balloon surface.
Table 2. Mesh settings that yield a mesh-independent solution.
Mesh element size (mm)
Implant diameter, d (cm)Domain Minimum Maximum
Implant surface 0.026 0.5 2–5
0–5mm from implant surface (target) 0.026 1.3 2–5
5–10mm from implant surface 0.026 2 2–5
>10mm from implant surface 0.195 4 2–4
0.240 5.6 5
Figure 4. Magnetic field profiles in head coil. (A) Magnetic field as a function of position along the coil axis in the center (blue) and two positions along the outer
casing of coil. (B) Magnetic field profiles horizontally and vertically across the coil at coil center (solid) and at each end of coil (dash).
Figure 5. Reproducibility of nanoparticle heating. (A) Heating rate of 2-cm diameter MNP-filled GliaSiteVR balloon in air obtained during nine independent trials at
three different field strengths. (B) Power absorption in equal volume MNP-filled test chambers immersed in different magnetic field strengths repeatedly over a
period of 5months, fitted to the expected magnetic field-squared relationship (solid line).
Figure 6. Temperature rise of the MNP filled balloon surface and at 2.5, 5, 7.5,
10 and 12.5mm radial distance in brain tissue-equivalent phantom.
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The computer simulations shown in Figure 8 demonstrate
therapeutic 4048.5 C heating of a 5-mm annular shell of
tumor bed tissue (target) around 2–5 cm diameter TBT
balloon implants in white matter with realistic temperature-
dependent perfusion (Figure 8(A)). Thermal conduction heat-
ing of tissue around the balloon implant is rapid and steady
state is achieved in less than 20min (Figure 8(B)). The
required total absorbed power of 2.19.3W for the different
size balloons corresponds to 0.3–0.6 W/mL of nanoparticle
solution, which generates the prescribed 40 C minimum
temperature throughout the 5-mm tumor bed while main-
taining the maximum below 48.5 C. Due to the rapid falloff
of temperature radially beyond the tumor bed, a very benefi-
cial localization of thermal dose occurs with minimal heating
of surrounding normal brain. As quantified in the tempera-
ture-volume histogram of Figure 8(D), 100% of the 5-mm rim
target tissue is heated above the prescribed 40 C threshold
for 2, 3, 4 or 5 cm diameter balloons, with only 8.716.5%
(or 0.51.2mm) of the target tissue exceeding 45 C. At the
same time, 95% of all surrounding normal brain tissue
remains below 38 C and is thus spared from significant ther-
mal toxicity.
4. Discussion
There are over 1 million solid tumor resections per year in
the United States which often leave positive margins after
surgery. Of these, there are approximately 24,000 glioblast-
oma and 50,000 single brain metastases cases that are candi-
dates for surgery [44,45]. It has been established that despite
the infiltrative nature of glioblastomas, they recur within
2 cm of the original resection margins in over 90% of
patients [46–49]. Thus, the ability to deliver a more effective
dose of radiation locally with less toxicity peripherally will
help optimize treatment of this disease. Post-op therapy
commonly includes radiation, however external beam treat-
ment alone is unable to deliver sufficient dose to effectively
treat tumor bed without complications in surrounding nor-
mal brain. Traditional multi-catheter brachytherapy seed
implants and interstitial therapies produce non-uniform dose
distributions with very high dose at the surface and much
lower dose midway between sources. This is particularly so
around the irregular shape resection cavities found in brain
several months after surgery and external beam radiation.
Considering all, current therapeutic approaches involving
Figure 7. (A) Human skull split-apart model filled with gelled brain tissue-equivalent phantom and 2-cm diameter magnetic nanoparticle filled balloon. (B)
Thermographic camera image of the head phantom central cross-section after immersion in a magnetic field for 20min. (C) Temperature profiles along the four
radial cross-sections marked on Figure 7(B) demonstrate the symmetry of heating around the nanoparticle filled balloon.
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extended fractionation EBRT followed sequentially by com-
bination local boost therapies are expensive and an incon-
venient use of remaining lifespan for the patient.
Combining hyperthermia with ionizing radiation enhances
the radiation response in tumors by several mechanisms.
Hyperthermia sensitizes tumor cells to radiation damage [50]
and inhibits mechanisms that repair radiation damage [51].
Hyperthermia stimulates blood flow and an associated
increase in tissue oxygenation has been demonstrated in
both animal [52,53] and human tumors [54]. Because much
of the tumor mass has lower blood flow, lower extracellular
pH, and is hypoxic and nutritionally deprived relative to sur-
rounding normal tissue, tumor cells are more sensitive to
hyperthermia [55,56]. Not only is oxygen a potent radiation
sensitizer, the corresponding enhanced perfusion can signifi-
cantly increase local delivery of chemotherapy [57] and
tumor immunotherapeutic agents such as large antibodies
[58]. The complimentary effects of adjuvant hyperthermia are
further enhanced since the cell cycle distribution of sensitiv-
ity to low LET radiation is the reverse of that of hyperthermia
[59]. Coincidentally, it has been shown in both transplantable
animal tumors [60] and human melanoma [12,13] that when
hyperthermia and radiation are delivered simultaneously, the
interaction between modalities, and therapeutic impact, are
greater than if they are separated by time [61].
Previous clinical trials have investigated the addition of
local heat to best available therapy of brain tumor volumes
using either interstitial catheter-based microwave antennas
[16] or ferromagnetic seeds [17,62,63], or multiple needle-
injected magnetic nanoparticles [18,19,64]. These studies all
demonstrated substantial impact of adjuvant hyperthermia in
spite of: (a) imperfect catheter or injection track geometry
relative to resection cavity shape, (b) non-uniform heat deliv-
ery to resection cavity wall, (c) non-uniform concentration of
magnetic particles within the target tissue, and (d) protracted
timing of sequentially delivered therapies that were applied
weeks apart and months after tumor resection [16–19].It is
well known that there are changes in the size and shape of
a resection cavity in the months following surgery due to
normal shifting of soft brain tissue as well as shrinkage and
distortion of brain from EBRT. This transforms the treatment
target from a simple annular rim of at-risk tissue around an
approximately spherical cavity immediately after surgery to a
convoluted irregular shape target. Moreover, the 3months
required to complete post-surgical healing and fractionated
radiotherapy provides critical time for tumor cells dislodged
at the time of surgery to migrate deeper into surrounding
normal brain. One impact of this post-surgical delay in treat-
ment is a moving, expanding target for local therapy. New
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Figure 8. Numerical simulations of MNP balloon implant heating. (A) Temperature-dependent blood perfusion scaling function F(T); (B) Simulated temperature as
a function of time at the implant surface and radially 5-mm (tumor edge) and 10-mm from the surface of a 3-cm diameter balloon; (C) Simulated temperatures
around 2, 3, 4, and 5 cm diameter TBT balloons implanted in tumor resection cavities in well-perfused white matter. (D) Simulated cumulative temperature-volume
histograms for 2, 3, 4, and 5 cm diameter balloons heating a 5-mm annular rim target of perfused white matter. Note that for all size balloons, 100% of the 5-mm
annular tumor bed target is heated above 40 C and about 50% of the target volume is heated above 41.8 C for balloon surface temperatures of 46.2–48.5 C.
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high concentration of magnetic nanoparticles throughout
the region of brain tumor to generate appropriate tempera-
ture distributions [65,66]. One study investigated the inverse
problem of calculating temperature within a solid tumor
mass induced from a shell of magnetic particles entirely sur-
rounding a spherical tumor [67,68].Recent advances in the
delivery of magnetic fluid hyperthermia were reviewed
recently [69] including filling a natural body cavity with mag-
netic nanoparticle solution [68]. Such approaches may be
feasible when local toxicity of the nanoparticles and accumu-
lation of magnetic material in the region are not an issue.
For applications in brain tumor therapy, it is generally pre-
ferred to avoid leaving magnetic material in the brain that
will complicate magnetic resonance follow up imaging.
As demonstrated in previous clinical trials that combined
highly heterogeneous interstitial heat and brachytherapy
dose distributions, HT offers a powerful boost to the RT anti-
tumor effect without increasing normal tissue complications
significantly. Even using interstitial implants delayed months
after surgery, thermoradiotherapy clinical trials in primary
GBM have [16] demonstrated a doubling of 2-year survival
[16,17] increased median survival from 13 to 24months [17],
and to 23.2months [19]. In retrospect, the difficulty in
obtaining uniform dose coverage of all at-risk tissue with
widely spaced ferroseeds, nanoparticles, or microwave anten-
nas implanted into the irregular shape annular rim target
around a resection cavity is easily appreciated. To improve
upon the above thermoradiotherapy results, a new technol-
ogy is required that can: (1) deliver heat and radiation doses
more uniformly to at-risk tumor bed; (2) deliver both treat-
ments simultaneously for maximum synergism; (3) be com-
patible with standard neurooncology procedures; and (4) be
applied immediately after surgery before proliferation and
spread of tumor cells into surrounding brain.
For this study, a magnetic induction heating system was
constructed with 26 30 19 cm3 head coil that accom-
plished the desired local heating of 2-cm diameter balloons
filled with commercially available 17mg/mL iron nanopar-
ticles. It is well known that along with nanoparticle heating
some amount of direct tissue heating results from induced
eddy currents which are proportional to magnetic field-
squared, frequency-squared, and radius-squared of eddy cur-
rent path in tissue [70,71]. It is also well known that for a
given size tissue load in a magnetic field, tissue will absorb
energy from the field and heat at a similar rate when
exposed to the same product of magnetic field and fre-
quency (H f) [72]. Clinical studies by Maier-Hauff et al.
[18,19] have demonstrated that MNP-based heat treatments
are safe and effective in humans using a 100 kHz magnetic
field up to 13.5 kA/m together with iron oxide nanoparticles
injected interstitially into brain, for an H f product of
1.35 A/mGHz [18,19]. The maximum output of this system is
1.07 A/mGHz as currently configured and only 0.8 A/mGHz
at the expected operating level. So the proposed TBT bal-
loon heating approach offers improved patient safety due to
reduced direct eddy current heating of brain relative to pre-
vious hyperthermia clinical trials that required higher field
strengths to activate a smaller volume of dispersed magnetic
material. Using a moderate 5.7 kA/m field at 133 kHz (45%
lower H f product than that used by Maier-Hauff et al. [19]
which should lead to 70% lower direct tissue heating), the
system produced the required 0.5W/mL within a 2-cm diam-
eter nanoparticle-filled balloon anywhere inside the head coil
including the broad minimum field ‘sweet spot’ in coil center
(Figure 4). Though this field is sufficient to heat human brain
around any of the proposed 2–5 cm diameter balloons,
higher fields are easily achieved safely if necessary and the
system was tested for over 60min continuous operation at
8.1 kA/m in the coil center [19], which produced 0.85W/mL
in the 2-cm diameter balloon. In subsequent application to
heating resection cavities in larger diameter tissue regions
such as human abdomen or pelvis, additional strategies may
be useful to further enhance local nanoparticle heating such
as power modulation of the magnetic field [73–75]. Our
experimental results with magnetic nanoparticles show excel-
lent repeatability of heating, even when reusing the same
nanoparticle solution and silicone balloon catheter >30
times over 5months. These experiments clearly demonstrate
that commercially available nanoparticles can be used to
produce therapeutic temperatures (e.g., 40–48 C) all around
implanted balloon catheters such as the GliaSiteVR and pre-
sumably the similarly constructed double wall balloon of
Figure 1. Moreover the experiments demonstrate repeatabil-
ity of heating characteristics after storing the MNP-filled bal-
loon in a refrigerator for long periods between trials.
Since the experimental phantom studies do not include
critically important blood perfusion, we conducted computa-
tional simulations to investigate the feasibility of heating per-
fused human tissue. Although the simulated geometry is
straightforward (concentric spheres), the temperature-
dependent parameter F(T) of Equation (2) transforms the bio-
heat equation into a non-linear partial differential equation
so that available analytical solutions (e.g., developed by
Rodrigues et al. [43] or Andra et al. [66]), are not applicable.
Thus, we performed numerical simulations using commer-
cially available software with a temperature-dependent blood
perfusion function that includes three white matter-specific
parameters: xb, Tcr, and a. Additionally, a b parameter
derived from muscle properties and c were introduced in
this study for T > Tcr ¼ 45 C to guarantee zero blood perfu-
sion above 48 C. Both the threshold of 48 C and the
Gaussian profile between 45 and 48 C are assumptions
based on experimental work performed in mice [42]. The
impact of this uncertainly above 45 C is limited for two rea-
sons [1]: the tissue volume above 45 C is only about 1-mm
in thickness immediately adjacent to the balloon (Figure
8(C)); and [2] we expect a thin coating (likely of the order of
1mm) of blood and/or cerebrospinal fluid surrounding the
balloon to have no perfusion and thus can exceed 45 C
without harm. Furthermore, we modeled healthy brain tissue
throughout the 5-mm annular shell target, though we might
anticipate somewhat impaired blood perfusion due to the
surgical resection. Thus, modeling healthy perfusion through-
out the 5-mm tumor bed should be a worst-case scenario,
such that we might use balloon surface temperatures some-
what lower than our simulations or expect to penetrate
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somewhat deeper than 5-mm with our 40 C goal. Despite
the simplicity of the anatomical model to date, these simula-
tions indicate that it is feasible to heat well-perfused brain
using the MNP balloon approach. Future numerical studies
will accommodate more precise anatomical models that
include the presence of large vessels, CSF, and the transient
behavior of blood perfusion (e.g [75].).
The expected outcome of using the proposed thermobra-
chytherapy balloon implant is the first ever clinically practical
device capable of delivering simultaneous and uniform HT
and RT to resection cavity wall targets. This device should
produce minimal normal tissue damage >10-mm from the
resection margin and significantly reduce the time (1week)
and cost of thermobrachytherapy. The technique is compat-
ible with existing surgical, radiation and chemotherapy pro-
cedures. Although this approach will require lower magnetic
field strength to heat the nanoparticle filled balloon than
previous clinical trials, contraindications to using this
approach will include the presence of large metallic objects
in the head, similar to previous clinical investigations of mag-
netic field heating inside the head [19,62,64,76–79]. By
adapting proven technologies like silicone balloon brain
implants [8,80] and inflatable catheter-based HDR brachy-
therapy [9,10] in combination with proven heating
approaches like magnetic field induced heating of ferromag-
netic seeds [71,77,79,81] and magnetic nanoparticles
[18,19,82], this approach should see expedited clinical imple-
mentation due to successful clinical precedent and estab-
lished regulatory pathway for all component technologies.
It has been 22 years since a randomized clinical trial
showed a statistically significant doubling of 2-year survival
over the best available combination treatment for GBM.
Among other challenges that limited the impact of that trial,
the protocol required a delay of 3.5months before sequential
delivery of local HT and RT treatments to the tumor bed via
a small number of interstitial implant catheters. It has been
30 years since pre-clinical data demonstrated a dramatic
enhancement of local RT effect without accompanying
increase in long term toxicity by combining heat and radi-
ation simultaneously [13]. The ensuing decades have seen no
advances in commercial equipment to deliver uniform heat
and radiation to a resection cavity tumor bed and no signifi-
cant improvement in survival or quality of life for the general
population of GBM patients. A system that can provide com-
bination HT and RT simultaneously for maximum TER and
uniformly distributed to cancer cells all around the resection
cavity is long overdue. The early prototype system first
described in a conference proceedings article [83] and tested
in this feasibility study addresses this dire need for new
equipment and offers the additional benefit that all thermor-
adiotherapy can be completed within 1week of surgery,
before tumor cell proliferation and expansion deeper into
surrounding brain.
One issue that has been considered carefully in this devel-
opment regards the ability to conform a primarily spherical
shape balloon into intimate contact with the resection cavity
wall for good thermal conduction out into surrounding brain.
The FDA-approved GliaSite balloon [84,85], used successfully
in over 500 brain tumor patients, provides excellent prece-
dent for the proposed thermobrachytherapy balloon. The
GliaSite provided a straight-forward protocol for determining
the balloon fill volume as well as the radiation dosing
scheme required to achieve the intended depth of penetra-
tion [86]. At the time of tumor resection, the balloon was
filled with an observed volume of saline to gently displace
the margins of the resection cavity into a spherical shape.
With experience, this was easily achieved with little to no
risk of creating untoward mass effect in surrounding brain.
The saline was subsequently withdrawn and the same vol-
ume of radioactive liquid used to refill the balloon for the
multi-day radiation treatment. Our proposed procedure will
replace the radiation fluid with a magnetic nanoparticle solu-
tion for heating and a retractable HDR brachytherapy source
inserted to the center of balloon. This configuration maxi-
mizes uniformity of radiation and heat delivered to the resec-
tion cavity wall with consequent spherically symmetric dose
distribution to surrounding brain [86]. A good illustration of
the preferred spherically symmetric dosimetry in brain
around a GliaSite balloon implant is shown in Chan et al.
[84]. Heating of the brain will be monitored via a tempera-
ture probe inside the thermobrachytherapy balloon and the
temperature gradient falloff into surrounding tissue deter-
mined via treatment planning. As with other hyperthermia
treatments, tissue temperature immediately adjacent to large
heat sinks like CSF spaces and large vascularity will not be
known exactly. However, past experience of our group with
GliaSite balloons, interstitial laser and microwave antenna
heat sources have shown that source placement can help
accommodate expected temperature heterogeneities while
some temperature variation within the treatment volume is
unavoidable.
Although this research paves the way for fast well-focused
therapy of at-risk tissue around a surgical resection cavity,
future clinical trials must establish whether local therapy for
GBM is sufficient to eliminate viable tumor cells in the resec-
tion cavity margin when treatment is completed immediately
after surgery or if there remains a need to add external
beam RT, systemic chemotherapy, and/or immune boost
therapies. The proposed 46–48 C balloon surface tempera-
tures simulated in this work are a proposed starting point for
clinical investigations; higher temperatures are easily
obtained if determined useful clinically. The current team of
neurooncologists involved in this project believe that in a
majority of patients, GBMs recur close to the original surgical
cavity and not several cm distant in brain. Thus a 48 C sur-
face temperature treating 5–8mm rim of tissue (depending
on surrounding perfusion) should be a good starting point
for clinical studies that might push higher in temperature
when tolerable clinically. The endpoint is overall patient sat-
isfaction, which includes not only duration of response, but
also time of therapy and quality of life (QOL) over the dur-
ation of response. The proposed approach anticipates
improved QOL from: (a) giving critical time back to the
patient by completing all therapy in 1week, (b) improving
the localization of HT and RT in tumor bed which should
reduce normal brain toxicity, and (c) reducing or eliminating
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EBRT which should further reduce neurocognitive deficit
throughout a much longer anticipated survival period.
5. Conclusions
We describe a dual-modality thermobrachytherapy (TBT) bal-
loon temporary implant device for treating at-risk tissue
around a GBM tumor resection cavity with HDR brachyther-
apy and simultaneous local heat via external magnetic field
activated nanoparticles. Temperature simulations of heating
in well-perfused white matter demonstrate the ability to heat
a 5-mm annular rim of tumor bed in brain to a therapeutic
40 48 C by absorbing <0.5W/mL in 2–5 cm diameter
nanoparticle-filled balloons. Laboratory measurements
repeated over a 5-month timeframe demonstrate the ability
to reproducibly deposit over 3 times the required power
density in a 2-cm diameter balloon filled with commercially
available GMP-manufactured magnetic nanoparticles (17mg/
mL iron) activated with a magnetic field of 5.7 kA/m at
133 kHz. This field is well below the level that has proven
safe in previous human clinical trials. The proposed TBT bal-
loon implant has the potential to simultaneously deliver radi-
ation and heat more uniformly to tumor bed than alternative
interstitial implant technologies and to generate a thermal
enhancement ratio up to 5.0 for significantly enhanced
therapeutic effect compared to RT treatment alone. The well-
localized conformal dosimetry obtained with this new device
should provide improved patient outcomes with lower com-
plications in surrounding healthy brain. The reduced overall
time of therapy applied immediately after surgery should
help improve quality of life as well as survival for patients
with glioblastoma multiforme.
Patents
Thomas Jefferson University has patent pending technology
with a published patent application for treating tumor bed
margins of a resection cavity with simultaneous heat and
radiation [87]. AMF Life Systems has patented technology for
induction coils and systems for magnetic hyperthermia [35].
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